← Leaderboards
John D Roback
Emory University
$16,074,929
Attributed
$18,302,239
Total exposure
17
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.3M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$34,308,050 · 18
By mechanism
P01$19,265,560 · 4
R01$9,478,251 · 3
R42$1,855,836 · 2
T32$1,728,095 · 1
U54$845,327 · 2
R38$704,001 · 1
Top collaborators
- Sean R Stowell11 shared
- Ann M Chahroudi3 shared
- Una T O'Doherty1 shared
Most similar at Emory University
Same institution · by research overlap
- Sean R Stowell$18,165,764
- James C. Zimring$24,599,687
- Nourine Ahmed Kamili$189,066
- Andrew S. Neish$13,307,399
- Rafi Ahmed$104,632,759
Others in their field
Top investigators on “Transfusion”
- Russell E Ware · Duke University$40,659,016
- Susan Fera Assmann · New England Research Institutes, Inc.$32,364,291
- Jeffrey Lee Carson · Univ Of Med/Dent Nj-R W Johnson Med Sch$30,236,292
- Gabriel Muyinda · Zambia National Blood Transfusion Srv$23,779,270
- Michael Rutledge Debaun · Vanderbilt University Medical Center$23,544,275
- Abhik Das · Research Triangle Institute$22,986,828
Research focus
TransfusionGrantResearch PersonnelBloodClinical ResearchErythrocytesPreventFundingTrainingErythrocyte TransfusionSafetyBlood BanksMonitorIn VitroSamplingIn VivoPhysiologicalProgramsCharacteristicsMorbidity - Disease RateInvestigationMedicineHazardLead
Grant awards (69)
Emory Pediatrics and Pathology Stimulating Access to Research in Residency (Emory-PP StARR).$409,275
R38 · FY2025 · HL
Training Grant in Transfusion Medicine$185,548
T32 · FY2025 · HL · contact PI
Emory Pediatrics and Pathology Stimulating Access to Research in Residency (Emory-PP StARR).$212,614
R38 · FY2024 · HL
Core 1: Sample Procurement and Clinical Core$88,878
U54 · FY2024 · CA · contact PI
Training Grant in Transfusion Medicine$78,837
T32 · FY2024 · HL · contact PI
Training Grant in Transfusion Medicine$94,389
T32 · FY2023 · HL · contact PI
Emory Pediatrics and Pathology Stimulating Access to Research in Residency (Emory-PP StARR).$82,112
R38 · FY2023 · HL
Core 1: Sample Procurement and Clinical Core$226,143
U54 · FY2022 · CA · contact PI
Training Grant in Transfusion Medicine$170,227
T32 · FY2022 · HL · contact PI
Training Grant in Transfusion Medicine$167,214
T32 · FY2021 · HL · contact PI
Engineering iPSC-RBCs for Transfusion$715,433
R01 · FY2020 · HL · contact PI
Core 1: Sample Procurement and Clinical Core$530,306
U54 · FY2020 · CA · contact PI
Engineering iPSC-RBCs for Transfusion$298,116
R01 · FY2020 · HL · contact PI
Training Grant in Transfusion Medicine$159,710
T32 · FY2020 · HL · contact PI
Serious Hazards of Transfusion & Cellular Therapies: Mechanisms and Intervention$1,642,651
P01 · FY2019 · HL · contact PI
Engineering iPSC-RBCs for Transfusion$591,082
R01 · FY2019 · HL · contact PI
Project 1: Identification and validation of biomarkers for RBC metabolic aging$225,174
P01 · FY2019 · HL · contact PI
Engineering iPSC-RBCs for Transfusion$98,785
R01 · FY2019 · HL · contact PI
Core A: Administrative Core$33,040
P01 · FY2019 · HL · contact PI
Microfluidic Technologies as Clinical Biomarker Platforms for Sickle Cell Gene Therapies$31,985
OT2 · FY2019 · HL · contact PI
Serious Hazards of Transfusion & Cellular Therapies: Mechanisms and Intervention$1,666,652
P01 · FY2018 · HL · contact PI
Engineering iPSC-RBCs for Transfusion$585,622
R01 · FY2018 · HL · contact PI
Project 1: Identification and validation of biomarkers for RBC metabolic aging$234,300
P01 · FY2018 · HL · contact PI
Training grant in transfusion medicine$69,021
T32 · FY2018 · HL · contact PI
Core A: Administrative Core$32,892
P01 · FY2018 · HL · contact PI
Serious Hazards of Transfusion & Cellular Therapies: Mechanisms and Intervention$1,669,016
P01 · FY2017 · HL · contact PI
Adverse effects of RBC transfusions: A unifying hypothesis$814,645
R01 · FY2017 · HL · contact PI
Engineering iPSC-RBCs for Transfusion$605,656
R01 · FY2017 · HL · contact PI
Project 1: Identification and validation of biomarkers for RBC metabolic aging$216,700
P01 · FY2017 · HL · contact PI
Training grant in transfusion medicine$127,087
T32 · FY2017 · HL · contact PI
Core A: Administrative Core$33,039
P01 · FY2017 · HL · contact PI
Serious Hazards of Transfusion & Cellular Therapies: Mechanisms and Intervention$1,742,630
P01 · FY2016 · HL · contact PI
Adverse effects of RBC transfusions: A unifying hypothesis$831,394
R01 · FY2016 · HL · contact PI
Project 1: Identification and validation of biomarkers for RBC metabolic aging$269,274
P01 · FY2016 · HL · contact PI
Training grant in transfusion medicine$152,100
T32 · FY2016 · HL · contact PI
Core A: Administrative Core$33,041
P01 · FY2016 · HL · contact PI
Serious Hazards of Transfusion & Cellular Therapies: Mechanisms and Intervention$1,917,160
P01 · FY2015 · HL · contact PI
Adverse effects of RBC transfusions: A unifying hypothesis$820,646
R01 · FY2015 · HL · contact PI
Project 1: Identification and validation of biomarkers for RBC metabolic aging$328,892
P01 · FY2015 · HL · contact PI
Training grant in transfusion medicine$132,288
T32 · FY2015 · HL · contact PI
Core A: Administrative Core$33,041
P01 · FY2015 · HL · contact PI
Adverse effects of RBC transfusions: A unifying hypothesis$871,475
R01 · FY2014 · HL · contact PI
Training grant in transfusion medicine$147,504
T32 · FY2014 · HL · contact PI
Training Grant in Transfusion Medicine (T32)$33,739
T32 · FY2013 · HL · contact PI
Serious Hazards of Transfusion & Cellular Therapies: Mechanisms and Intervention$1,820,356
P01 · FY2012 · HL · contact PI
Serious Hazards of Transfusion & Cellular Therapies: Mechanisms and Interventio$1,820,356
P01 · FY2012 · HL · contact PI
Adverse effects of RBC transfusions: A unifying hypothesis$337,051
R01 · FY2012 · HL · contact PI
Adverse effects of RBC transfusions: A unifying hypothesis$186,642
R01 · FY2012 · HL · contact PI
Training Grant in Transfusion Medicine (T32)$96,729
T32 · FY2012 · HL · contact PI
Serious Hazards of Transfusion & Cellular Therapies: Mechanisms and Intervention$1,845,272
P01 · FY2011 · HL · contact PI
Adverse effects of RBC transfusions: A unifying hypothesis$478,860
R01 · FY2011 · HL · contact PI
Training Grant in Transfusion Medicine (T32)$113,702
T32 · FY2011 · HL · contact PI
Serious Hazards of Transfusion & Cellular Therapies: Mechanisms and Intervention$1,844,076
P01 · FY2010 · HL · contact PI
Adverse effects of RBC transfusions: A unifying hypothesis$469,066
R01 · FY2010 · HL · contact PI
Novel devices for rapid blood compatibility testing$393,956
R42 · FY2010 · DK · contact PI
Serious Hazards of Transfusion & Cellular Therapies: Mechanisms and Intervention$1,857,998
P01 · FY2009 · HL · contact PI
Adverse effects of RBC transfusions: A unifying hypothesis$405,778
R01 · FY2009 · HL · contact PI
Novel devices for rapid blood compatibility testing$395,767
R42 · FY2009 · DK · contact PI
Novel devices for rapid blood compatibility testing$574,049
R42 · FY2008 · DK · contact PI
Vaccine-enhanced DLI to prevent cancer recurrence after stem cell transplantation$100,000
R41 · FY2006 · HL · contact PI
Automated high-throughput detection anti-HLA antibodies$99,510
R41 · FY2006 · HL · contact PI
Allogeneic BMT and adoptive antiviral immunotherapy$342,000
R01 · FY2005 · HL
Allogeneic BMT and adoptive antiviral immunotherapy$342,000
R01 · FY2004 · HL
Rapid quantitation of residual WBCs in filtered blood$99,509
R41 · FY2004 · HL
Novel devices for rapid blood compatibility testing$96,232
R42 · FY2004 · HL
Novel devices for rapid blood compatibility testing$395,832
R42 · FY2003 · HL
Allogeneic BMT and adoptive antiviral immunotherapy$342,000
R01 · FY2003 · HL
Allogeneic BMT and adoptive antiviral immunotherapy$342,000
R01 · FY2002 · HL
NOVEL DEVICES FOR RAPID BLOOD COMPATIBILITY TESTING$99,976
R41 · FY2001 · HL